Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.64B | 18.41B | 13.80B | 11.11B | 10.59B |
| Total Depreciation and Amortization | 2.00B | 1.90B | 1.89B | 1.83B | 1.77B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.27B | 2.40B | 3.11B | 3.38B | 1.85B |
| Change in Net Operating Assets | -8.09B | -6.64B | -7.86B | -7.00B | -5.38B |
| Cash from Operations | 16.81B | 16.06B | 10.94B | 9.32B | 8.82B |
| Capital Expenditure | -7.84B | -6.79B | -6.05B | -5.58B | -5.06B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -661.00M | -549.70M | -300.00K | -948.00M | -948.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.47B | -2.75B | -5.06B | -4.95B | -3.30B |
| Cash from Investing | -10.97B | -10.09B | -11.11B | -11.48B | -9.30B |
| Total Debt Issued | 13.17B | 13.17B | 11.43B | 11.43B | 11.42B |
| Total Debt Repaid | -5.12B | -2.07B | -1.07B | 840.10M | -2.52B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4.11B | -4.65B | -4.39B | -3.70B | -2.50B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.38B | -5.21B | -5.03B | -4.86B | -4.68B |
| Other Financing Activities | -772.00M | -792.80M | -809.90M | -787.50M | -491.00M |
| Cash from Financing | -2.21B | 440.30M | 120.60M | 2.92B | 1.23B |
| Foreign Exchange rate Adjustments | 372.00M | 10.30M | 205.50M | -129.60M | -297.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.00B | 6.42B | 151.50M | 632.30M | 449.00M |